Hartford Healthcare — Hartford, Connecticut

Public research footprint of Hartford Healthcare, compiled from the ClinicalTrials.gov public registry.

121

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Locally Advanced Unresectable Gastroesophageal Junction (GEJ)… · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or Cancer · Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

Recently updated registry entries

NCT06901531 — A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With… (Recruiting)
NCT07252232 — Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal… (Recruiting)
NCT00310180 — Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Hartford Healthcare?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.